What changed
$CL — AVOID 📊
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally.
🎯 Q1 FY26 | Rev $5B | EPS $0.97 vs $0.94 🟢 | Margin 19.4%
💡 Market expects consistent low-single-digit organic growth and margin maintenance. The variant view of improving growth from fading pet food headwinds and EM recovery is already partially priced into estimates. No significant gap exists to drive outperformance.
📉 Reward/Risk: 0.6:1
🏢 Business Quality: 8/10 - Strong brand moat in oral, pet, and home care; consistent cash generation, but mature categories limit upside.
📊 Valuation: fair — P/E 23.2x fwd, EV/EBITDA ~16x, FCF yield 3.4%. In line with peers (PG, UL) and history. Multiple expansion unlikely without growth surprise.
🔮 Catalyst: Q2 2026 earnings (est. July 2026)
Also in play: $BWA $MGA $LEA $GNTX $ALV $X
Why it matters
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally.